Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why XenoPort, Inc. (XNPT) Shares Zoomed Higher

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

XenoPort, Inc. (NASDAQ:XNPT)

What: Shares of XenoPort, Inc. (NASDAQ:XNPT), a biopharmaceutical company focused on developing neurological disorder therapies, added as much as 19% today following the release of early stage results for XP23829 for the treatment of relapsing-remitting multiple sclerosis.

So what: XP23829, a prodrug of monomethyl fumarate (MMF), was tested over two studies in five separate cohorts with a sixth group of healthy subjects receiving Biogen Idec Inc (NASDAQ:BIIB)‘s Tecfidera as the control group. The study demonstrated that Tecfidera, a dimethyl fumarate compound that breaks down to MMF in the body, and XP23829 for the 400mg dose, enzymatically converted to about the same amount of MMF in the body when dosed without food. XP23829 was also well-tolerated in the studies. XenoPort, Inc. (NASDAQ:XNPT) noted enough positive evidence from these early stage results to move XP23829 into mid-stage studies.

Now what: The allure of MMF-based MS treatments is that they could become a less-frequently taken and longer-term solution than DMF-based drugs like Biogen Idec Inc (NASDAQ:BIIB)’s Tecfidera. Ultimately, though, we’re only talking about an early-stage trial here. XenoPort, Inc. (NASDAQ:XNPT) still has to establish the proper dosing then outline the next step of its study to the Food and Drug Administration. If this were a baseball game, XenoPort, Inc. (NASDAQ:XNPT) scored a run with a double in the bottom of the second inning, but still has seven innings left to go. I’d be excited as well if I was a XenoPort, Inc. (NASDAQ:XNPT) shareholder, but the reality is that XP23829 becoming a game-changer is at least a few years off at best.

The article Why XenoPort Shares Zoomed Higher originally appeared on is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!